Antigen-specific active immunotherapy for ovarian cancer.

CONCLUSIONS: We conclude that despite promising immunological responses, no clinically effective antigen-specific active immunotherapy is yet available for ovarian cancer. Results should be interpreted cautiously, as review authors found a significant dearth of relevant information for assessment of risk of bias in both RCTs and NRSs. PMID: 30199097 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30199097?dopt=Abstract

Source: Cochrane Database of Systematic Reviews - September 10, 2018 Category: General Medicine Authors: Paijens ST, Leffers N, Daemen T, Helfrich W, Boezen HM, Cohlen BJ, Melief CJ, de Bruyn M, Nijman HW Tags: Cochrane Database Syst Rev Source Type: research